Genocea Biosciences (NASDAQ:GNCA) Stock Rating Reaffirmed by HC Wainwright

Share on StockTwits

HC Wainwright restated their buy rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report report published on Monday, AnalystRatings.com reports.

A number of other equities research analysts also recently weighed in on the company. ValuEngine raised Genocea Biosciences from a hold rating to a buy rating in a research report on Friday, November 1st. Needham & Company LLC reissued a buy rating and set a $10.00 target price on shares of Genocea Biosciences in a research report on Thursday, October 24th. Finally, Zacks Investment Research downgraded Genocea Biosciences from a buy rating to a hold rating in a research report on Tuesday, October 29th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $12.94.

GNCA stock traded up $0.01 during trading on Monday, reaching $2.25. 241,400 shares of the stock were exchanged, compared to its average volume of 297,488. Genocea Biosciences has a twelve month low of $1.99 and a twelve month high of $11.28. The company has a market capitalization of $56.48 million, a P/E ratio of -0.61 and a beta of 2.43. The stock has a 50 day simple moving average of $2.60 and a 200-day simple moving average of $3.16. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.45.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, October 24th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.17. Equities analysts predict that Genocea Biosciences will post -1.78 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in GNCA. FNY Investment Advisers LLC lifted its stake in Genocea Biosciences by 88.2% during the third quarter. FNY Investment Advisers LLC now owns 253,000 shares of the biotechnology company’s stock worth $733,000 after purchasing an additional 118,600 shares during the period. Citadel Advisors LLC bought a new position in Genocea Biosciences during the second quarter worth about $68,000. D. E. Shaw & Co. Inc. bought a new position in Genocea Biosciences during the second quarter worth about $84,000. Cubist Systematic Strategies LLC bought a new position in Genocea Biosciences during the second quarter worth about $40,000. Finally, Morgan Stanley bought a new position in Genocea Biosciences during the second quarter worth about $26,000. 56.33% of the stock is currently owned by institutional investors and hedge funds.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

See Also: The risks of owning bonds

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Extremely Negative News Coverage Extremely Likely to Impact Kiwa Bio-Tech Products Group  Share Price
Extremely Negative News Coverage Extremely Likely to Impact Kiwa Bio-Tech Products Group Share Price
Brokers Set Expectations for WESCO International, Inc.’s Q1 2020 Earnings
Brokers Set Expectations for WESCO International, Inc.’s Q1 2020 Earnings
Calyxt Inc Forecasted to Earn FY2019 Earnings of  Per Share
Calyxt Inc Forecasted to Earn FY2019 Earnings of Per Share
South Mountain Merger Corp.’s  Lock-Up Period Will Expire  on December 17th
South Mountain Merger Corp.’s Lock-Up Period Will Expire on December 17th
FY2019 EPS Estimates for Macerich Co Decreased by KeyCorp
FY2019 EPS Estimates for Macerich Co Decreased by KeyCorp
Dream Office Real Estate Investment Trst  Sets New 12-Month High Following Insider Buying Activity
Dream Office Real Estate Investment Trst Sets New 12-Month High Following Insider Buying Activity


 
© 2006-2019 Zolmax.